These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 20933338)
41. [Ophthalmic disorders as a manifestation of Parkinson's disease]. Chesnokova NB; Pavlenko TA; Ugrumov MV Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(9):124-131. PubMed ID: 29053133 [TBL] [Abstract][Full Text] [Related]
42. Glutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neurons. Garrido M; Tereshchenko Y; Zhevtsova Z; Taschenberger G; Bähr M; Kügler S Acta Neuropathol; 2011 Apr; 121(4):475-85. PubMed ID: 21191602 [TBL] [Abstract][Full Text] [Related]
43. Common pathophysiology affecting diabetic retinopathy and Parkinson's disease. Tian T; Li Z; Lu H Med Hypotheses; 2015 Oct; 85(4):397-8. PubMed ID: 26141638 [TBL] [Abstract][Full Text] [Related]
44. [Myeloperoxidase in the neurodegenerative process of Parkinson's disease]. Teismann P Dtsch Med Wochenschr; 2014 Jan; 139(3):99-102. PubMed ID: 24277448 [TBL] [Abstract][Full Text] [Related]
45. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Hirsch EC; Hunot S Lancet Neurol; 2009 Apr; 8(4):382-97. PubMed ID: 19296921 [TBL] [Abstract][Full Text] [Related]
46. Differential vulnerability to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of dopaminergic and cholinergic neurons in the monkey mesopontine tegmentum. Herrero MT; Hirsch EC; Javoy-Agid F; Obeso JA; Agid Y Brain Res; 1993 Oct; 624(1-2):281-5. PubMed ID: 7902770 [TBL] [Abstract][Full Text] [Related]
47. [Anaesthesia and Parkinson's disease]. Chhor V; Karachi C; Bonnet AM; Puybasset L; Lescot T Ann Fr Anesth Reanim; 2011; 30(7-8):559-68. PubMed ID: 21530145 [TBL] [Abstract][Full Text] [Related]
49. Adipose-derived human mesenchymal stem cells induce long-term neurogenic and anti-inflammatory effects and improve cognitive but not motor performance in a rat model of Parkinson's disease. Schwerk A; Altschüler J; Roch M; Gossen M; Winter C; Berg J; Kurtz A; Akyüz L; Steiner B Regen Med; 2015 May; 10(4):431-46. PubMed ID: 26022763 [TBL] [Abstract][Full Text] [Related]
50. A tale on animal models of Parkinson's disease. Bezard E; Przedborski S Mov Disord; 2011 May; 26(6):993-1002. PubMed ID: 21626544 [TBL] [Abstract][Full Text] [Related]
51. The retina in Parkinson's disease. Archibald NK; Clarke MP; Mosimann UP; Burn DJ Brain; 2009 May; 132(Pt 5):1128-45. PubMed ID: 19336464 [TBL] [Abstract][Full Text] [Related]
52. Neurotrophic factors for the treatment of Parkinson's disease. Sullivan AM; Toulouse A Cytokine Growth Factor Rev; 2011 Jun; 22(3):157-65. PubMed ID: 21689963 [TBL] [Abstract][Full Text] [Related]
53. Animal models of Parkinson's disease in rodents induced by toxins: an update. Hirsch EC; Höglinger G; Rousselet E; Breidert T; Parain K; Feger J; Ruberg M; Prigent A; Cohen-Salmon C; Launay JM J Neural Transm Suppl; 2003; (65):89-100. PubMed ID: 12946051 [TBL] [Abstract][Full Text] [Related]
54. Parkinson's disease and enhanced inflammatory response. Stojkovska I; Wagner BM; Morrison BE Exp Biol Med (Maywood); 2015 Nov; 240(11):1387-95. PubMed ID: 25769314 [TBL] [Abstract][Full Text] [Related]
55. Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection. Berg D J Neural Transm Suppl; 2006; (71):123-32. PubMed ID: 17447423 [TBL] [Abstract][Full Text] [Related]